DiaMedica Therapeutics Inc(DMAC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.71 | Insider Own | 43.33% | Shs Outstand | 53.9M | Perf Week | 10.31% |
| Market Cap | 0.51B | Forward P/E | - | EPS next Y | 2.92% | Insider Trans | - | Shs Float | 30.6M | Perf Month | 15.11% |
| Enterprise Value | 0.47B | PEG | - | EPS next Q | -0.21 | Inst Own | 18.44% | Short Float | 17.15% | Perf Quarter | 50.16% |
| Income | -0.04B | P/S | - | EPS this Y | -10% | Inst Trans | 1.57% | Short Ratio | 27.99 | Perf Half Y | 57.36% |
| Sales | 0.00B | P/B | 13.39 | EPS next 5Y | -9.82% | ROA | -98.18% | Short Interest | 5.24M | Perf YTD | 19.6% |
| Book/sh | 0.71 | P/C | 11.8 | EPS past 3/5Y | -10.48% 2.31% | ROE | -114.62% | 52W High | -8.63% ($10.42) | Perf Year | 42.3% |
| Cash/sh | 0.81 | P/FCF | - | Sales past 3/5Y | - | ROIC | -97.75% | 52W Low | 81.51% ($5.24) | Perf 3Y | 342.79% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -3.42% | Gross Margin | - | Volatility(W/M) | 7.85% 6.66% | Perf 5Y | 141.01% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.55 | Perf 10Y | 141.38% |
| Dividend Ex-Date | - | Quick Ratio | 6.72 | EPS Q/Q | -4.97% | Profit Margin | - | RSI (14) | 67.95 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.72 | Sales Q/Q | - | SMA20 | 13.5% ($8.39) | Beta | 0.97 | Target Price | $15.5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/10 | SMA50 | 26.01% ($7.55) | Rel Volume | 1.05 | Prev Close | $9.82 |
| Employees | 35 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 5.43% - | SMA200 | 33.96% ($7.11) | Avg Volume(3M) | 0.19M | Price | $9.52 |
| IPO | 2008/1/4 | Option/Short | Yes/Yes | Trades | 1874 | Volume | 196,521 | Change | -3.05% |
🧬 This is a clinical-stage biotech company developing linvecalinase alfa, a novel drug candidate based on a recombinant kallikrein-1 protein. The company is focused on clinical development for vascular diseases as its core indications, including acute ischemic stroke and preeclampsia (toxemia of pregnancy), and operates as a pipeline-driven company with no approved products to date.
Over the past 1 year, on the higher side
9% below its 1-year high.
Traded about as much as usual. That is 105% of its average volume.
DMAC has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -10.0% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +141.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 18.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #217 of 594 in the industry
Based on market cap of $513M.
CBIO#215 Crescent Biopharma Inc $523M PER - 
ARVN#216 Arvinas Inc $517M PER 49.3 DMAC#217 DiaMedica Therapeutics Inc $513M PER - 
INDP#218 Indaptus Therapeutics Inc $513M PER - 
OCS#219 Oculis Holding AG $509M PER - 
FAQ
What kind of company is DMAC?
DMAC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DMAC?
The market cap of DMAC is approximately $513M, ranking 3,139 within its sector.
What is the 52-week high and low for DMAC?
DMAC has recorded a 52-week high of $10.42 and a low of $5.24.
